CRISPR Therapeutics

first CRISPR medicine in history, FDA approved Dec 2023 for SCD and Jan 2024 for TDT; ~1,000 US patients ≥12 yr eligible; paediatric sNDA under review 2026.

Country: Switzerland
Ticker: CRSP

FDA approved EMA approved

Coverage

	CN	EU	US
genome-engineering	✓	✓	✓
regenerative-personalized	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Funding	As of December 31, 2025, the company had cash, cash equivalents, and marketable securities of $1,975.8 million. It has a history of recurring losses and will require additional capital.	crisprtx.gcs-web.com · sec.gov
Production site	Wholly-owned, GMP manufacturing facility located in Framingham, Massachusetts.	crisprtx.com · crisprtx.gcs-web.com · ir.crisprtx.com · sec.gov
Capacity	Provides end-to-end production capabilities for its cell therapy portfolio, supporting both clinical and commercial supply.	crisprtx.gcs-web.com · ir.crisprtx.com
Regulatory approval	FDA approved CASGEVY for SCD and TDT in December 2023 (12+ years) and in 2026 for children 2 years and older.	ir.crisprtx.com · last10k.com · pmc.ncbi.nlm.nih.gov · fda.gov
Headcount	Estimates range from approximately 304 to 393 employees as of mid-2026. medium confidence	altindex.com · profit.com
Revenue	Reported $76 million in revenue for Q2 2026 and $116 million for full year 2025.	crisprtx.gcs-web.com · ir.crisprtx.com · last10k.com

Independent sources: altindex.com · crisprtx.com · crisprtx.gcs-web.com · fda.gov · ir.crisprtx.com · last10k.com · pmc.ncbi.nlm.nih.gov · profit.com · sec.gov

Technologies

Name	Cluster	Risk
Genome editing	genome-engineering	Medium	→
Personalized & regenerative medicine	regenerative-personalized	Medium	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.